^
    4years
    Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico. (PubMed, Oncotarget)
    Compared to previously published data, Hispanic CMML patients from Puerto Rico in this study had significantly lower mutation rates in ASXL1 and SETBP1, and a higher rate of muTET2/wtASXL1. The findings raise the possibility of a favorable prognosis in Hispanic CMML patients.
    Journal • Clinical
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • SETBP1 (SET Binding Protein 1)
    |
    NRAS mutation • DNMT3A mutation • ASXL1 mutation • TET2 mutation
    |
    Myeloid Molecular Profile